These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24517435)

  • 41. Role of T cells in graft rejection and transplantation tolerance.
    Issa F; Schiopu A; Wood KJ
    Expert Rev Clin Immunol; 2010 Jan; 6(1):155-69. PubMed ID: 20383898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Awards in Transplantation Science Recognize the Best Manuscripts Published in Transplantation.
    Tullius SG; Grey ST; Issa F
    Transplantation; 2016 Feb; 100(2):249-50. PubMed ID: 26813405
    [No Abstract]   [Full Text] [Related]  

  • 43. Everolimus and minimization of cyclosporine in renal transplantation: 24-month follow-up of the EVEREST study.
    Ponticelli C; Salvadori M; Scolari MP; Citterio F; Rigotti P; Veneziano A; Bartezaghi M;
    Transplantation; 2011 May; 91(10):e72-3. PubMed ID: 21540717
    [No Abstract]   [Full Text] [Related]  

  • 44. Towards the identification of biomarkers of transplantation tolerance.
    Turka LA; Lechler RI
    Nat Rev Immunol; 2009 Jul; 9(7):521-6. PubMed ID: 19483711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts.
    Cooper JE; Gralla J; Chan L; Wiseman AC
    Clin Transpl; 2011; ():359-64. PubMed ID: 22755431
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation.
    Wang X; Wang W; Xu J; Le Q
    Transplant Proc; 2013 Mar; 45(2):528-37. PubMed ID: 23267787
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The mechanisms of chronic kidney damage in renal transplant and their possible reversibility].
    Schena FP; Maiorano A; Rossini M
    G Ital Nefrol; 2008; 25 Suppl 44():S11-4. PubMed ID: 19048580
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
    Hao WJ; Zong HT; Cui YS; Zhang Y
    Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Markers of acute rejection and graft acceptance in liver transplantation.
    Germani G; Rodriguez-Castro K; Russo FP; Senzolo M; Zanetto A; Ferrarese A; Burra P
    World J Gastroenterol; 2015 Jan; 21(4):1061-8. PubMed ID: 25632178
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Approaching the promise of operational tolerance in clinical transplantation.
    Bishop GA; Ierino FL; Sharland AF; Hall BM; Alexander SI; Sandrin MS; Coates PT; McCaughan GW
    Transplantation; 2011 May; 91(10):1065-74. PubMed ID: 21544029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation.
    Ashton-Chess J; Giral M; Brouard S; Soulillou JP
    Transplantation; 2007 Nov; 84(10):1215-9. PubMed ID: 18049104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Renal Revival: The Hidden Benefit of Antirejection Medications.
    Koratala A; Kazory A
    Transplantation; 2018 Nov; 102(11):e481-e482. PubMed ID: 30048395
    [No Abstract]   [Full Text] [Related]  

  • 54. Conversion to sirolimus in kidney transplant recipients: a single-center study.
    Ganji MR; Hakemi MS; Esfehani F; Alatab S; Naderi GH
    Iran J Kidney Dis; 2013 Jul; 7(4):309-15. PubMed ID: 23880809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Early steroid withdrawal after renal transplantation.
    Colaneri J
    Nephrol Nurs J; 2006; 33(1):89-90. PubMed ID: 16538935
    [No Abstract]   [Full Text] [Related]  

  • 56. Posttransplant sCD30 as a biomarker to predict kidney graft outcome.
    Süsal C; Opelz G
    Clin Chim Acta; 2012 Sep; 413(17-18):1350-3. PubMed ID: 22037199
    [TBL] [Abstract][Full Text] [Related]  

  • 57. WOFIE stimulates regulatory T cells: a 2-year follow-up of renal transplant recipients.
    Dresske B; Haendschke F; Lenz P; Ungefroren H; Jenisch S; Exner B; El Mokhtari NE; Lu T; Zavazava N; Faendrich F
    Transplantation; 2006 Jun; 81(11):1549-57. PubMed ID: 16770244
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of a change in immunosuppressive regimen with hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation.
    Yong K; Nguyen HD; Hii L; Chan DT; Boudville N; Messineo A; Lim EM; Dogra GK; Lim WH
    Am J Hypertens; 2013 Jul; 26(7):843-9. PubMed ID: 23443728
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.